Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine.

Twenty-five healthy volunteers were given 100 mg caffeine orally and several estimates of cytochrome P450 1A2 (CYP1A2) activity were evaluated. The validation was performed by correlation of different parameters in plasma, saliva, and urine to two measures of caffeine clearance, CL(oral) and CL(137X-->17X) that served as standards of reference. Two subjects were excluded because of noncompliance with a caffeine-free diet. In the remaining 23 subjects, both plasma and saliva total clearances of caffeine were highly correlated with each other (r(s) = 0.97, p < 0.0001). The ratio 17X/137X restricted to one sampling point taken 4 hours after dose, showed a high correlation (r(s)) with CL(oral) and CL(137X-->17X) in plasma (0.84/0.83) and saliva (0.82/0.77) (p < 0.0001 for all the correlation values) where 17X is 1,7-dimethylxanthine (paraxanthine) and 137X is 1,3,7-trimethylxanthine (caffeine). Additionally, the ratio (AFMU + 1U + 1X + 17U + 17X)/137X in a 0-24 hours urine sampling showed the highest correlation with CL(137X-->17X) (r(s) = 0.85, p < 0.001) where AFMU is 5-acetylamino-6-formylamino-3-methyluracil, 1U is 1-methyluracil, 1X is 1-methylxanthine, and 17U is 1,7-dimethyluric acid. The major estimates of CYP1A2 activity were significantly less in nonsmoking females, and this probably was related to the use of oral contraceptives in this subpopulation. In summary, among caffeine-based approaches for CYP1A2, the authors recommend either plasma or saliva 17X/137X ratio and the urinary (AFMU + 1U + 1X + 17U + 17X)/137X ratio during a sampling interval of at least 8 hours, starting at time zero since caffeine intake. These indices are simple, reliable, and relatively inexpensive estimates of CYP1A2 activity to be used in the study of human populations.

[1]  K. Laine,et al.  Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy , 1999, Clinical pharmacology and therapeutics.

[2]  J. A. Carrillo,et al.  Caffeine metabolism in a healthy Spanish population: N‐Acetylator phenotype and oxidation pathways , 1994, Clinical pharmacology and therapeutics.

[3]  P. Beaune,et al.  Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. , 1996, Pharmacogenetics (London).

[4]  U. Fuhr,et al.  Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. , 1994, Pharmacogenetics.

[5]  L. Bertilsson,et al.  The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. , 2003, British journal of clinical pharmacology.

[6]  E. Perucca,et al.  The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: a comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate. , 1996, Therapeutic drug monitoring.

[7]  D. Grant,et al.  A simple test for acetylator phenotype using caffeine. , 1984, British journal of clinical pharmacology.

[8]  D. Grant,et al.  Isolation and identification of 5-acetylamino-6-formylamino-3-methyluracil as a major metabolite of caffeine in man. , 1983, Drug metabolism and disposition: the biological fate of chemicals.

[9]  L. Bertilsson,et al.  Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of Clozapine: Evidence from a Therapeutic Drug Monitoring Service , 1994, Therapeutic drug monitoring.

[10]  U. Fuhr,et al.  Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. , 1999, Pharmacogenetics.

[11]  M. Butler,et al.  Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[12]  R. Hayes,et al.  Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. , 1992, Pharmacogenetics.

[13]  W. Fleischhacker,et al.  Influence of patient-related variables on clozapine plasma levels. , 1990, The American journal of psychiatry.

[14]  K. Brøsen,et al.  Single‐dose kinetics of clomipramine: Relationship to the sparteine and S‐mephenytoin oxidation polymorphisms , 1994, Clinical pharmacology and therapeutics.

[15]  R. Berecz,et al.  Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients. , 1999, Journal of clinical psychopharmacology.

[16]  M M Callahan,et al.  Comparison of caffeine metabolism in three nonsmoking populations after oral administration of radiolabeled caffeine. , 1983, Drug metabolism and disposition: the biological fate of chemicals.

[17]  T. J. Preston,et al.  Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test. , 1998, British journal of clinical pharmacology.

[18]  S. Spielberg,et al.  A urinary metabolite ratio that reflects systemic caffeine clearance , 1987, Clinical pharmacology and therapeutics.

[19]  J. A. Carrillo,et al.  Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. , 1998, Journal of clinical psychopharmacology.

[20]  S. Schenker,et al.  Impaired elimination of caffeine by oral contraceptive steroids. , 1980, The Journal of laboratory and clinical medicine.

[21]  J. Sacristán,et al.  Use of Salivary Caffeine Tests to Assess the Inducer Effect of a Drug on Hepatic Metabolism , 1996, The Annals of pharmacotherapy.

[22]  G. Tucker,et al.  Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. , 1996, Pharmacogenetics.

[23]  S. Cnattingius,et al.  Dietary caffeine as a probe agent for assessment of cytochrome P4501A2 activity in random urine samples. , 1999, British journal of clinical pharmacology.

[24]  C. Alm,et al.  Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: An interaction study with fluvoxamine and ketoconazole as in vivo inhibitors , 1998, Clinical pharmacology and therapeutics.

[25]  T. Someya,et al.  Lower plasma levels of haloperidol in smoking than in nonsmoking schizophrenic patients. , 1999, Therapeutic drug monitoring.

[26]  K. Brøsen,et al.  Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans. , 1996, Therapeutic drug monitoring.

[27]  B. K. Park,et al.  An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes. , 1993, Biochemical pharmacology.

[28]  O. Spigset,et al.  Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans , 1995, Clinical pharmacology and therapeutics.

[29]  B. Tang,et al.  The use of caffeine for enzyme assays: A critical appraisal , 1993, Clinical pharmacology and therapeutics.

[30]  C. Alm,et al.  Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. , 1994, British journal of clinical pharmacology.

[31]  B. Tang,et al.  Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements. , 1994, Pharmacogenetics.

[32]  B. Ring,et al.  Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. , 1996, The Journal of pharmacology and experimental therapeutics.

[33]  M. Folan,et al.  Inhibition of Caffeine Metabolism by Estrogen Replacement Therapy in Postmenopausal Women , 1999, Journal of clinical pharmacology.

[34]  N. Benowitz,et al.  Validation of urine caffeine metabolite ratios with use of stable isotope‐labeled caffeine clearance , 1996, Clinical pharmacology and therapeutics.

[35]  P. Bennett,et al.  Caffeine as a metabolic probe: a comparison of the metabolic ratios used to assess CYP1A2 activity. , 1995, British journal of clinical pharmacology.

[36]  C. Alm,et al.  Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity , 1996, Clinical pharmacology and therapeutics.

[37]  F. Guengerich.  Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy. , 1988, Cancer research.

[38]  S. Loft,et al.  A fluvoxamine-caffeine interaction study. , 1996, Pharmacogenetics.

[39]  P. Guzelian,et al.  Characterization of human liver cytochromes P-450 involved in theophylline metabolism. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[40]  P. Steer,et al.  Saliva as a valid alternative to serum in monitoring intravenous caffeine treatment for apnea of prematurity. , 1996, Therapeutic drug monitoring.

[41]  J. Miners,et al.  Quantitative assessment of caffeine partial clearances in man. , 1986, British journal of clinical pharmacology.

[42]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[43]  I. Roots,et al.  Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: Coincidence with plasma clearance and breath test , 1994, Clinical pharmacology and therapeutics.

[44]  L. Heilbronn,et al.  Oral contraceptive steroids impair the elimination of theophylline. , 1983, The Journal of laboratory and clinical medicine.

[45]  F. Gonzalez,et al.  Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. , 1992, Pharmacogenetics.

[46]  A. Guillouzo,et al.  Evidence for the involvement of several cytochromes P-450 in the first steps of caffeine metabolism by human liver microsomes. , 1991, Drug metabolism and disposition: the biological fate of chemicals.